Department of Rheumatology, Qingdao Hiser Hospital Affiliated with Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong Province, China.
Department of Traditional Chinese Medicine Classics, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, Shandong, China.
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241300137. doi: 10.1177/03946320241300137.
Pyoderma gangrenosum (PG) is a rare noninfectious neutrophilic dermatosis characterized by recurrent, painful ulcers that commonly affect the lower extremities but can also involve other parts of the body. Over half of patients with PG have concomitant systemic immune diseases, with the association of PG with systemic sclerosis (SSc) being extremely rare. Treatment of PG primarily involves local therapy, steroids, and immunosuppressants, with an increasing emphasis on biologic agents. Among these, tumor necrosis factor-alpha (TNF-α) antagonists are considered effective. The patient in this report was an elderly female with a history of systemic sclerosis for many years and initially presented with gangrenous ulcers on the fingertips. After inconclusive conventional treatment, adalimumab was added for 5 weeks, resulting in disease suppression, a reduction in ulcer size, and re-epithelialization of the skin lesions after 6 months.
坏疽性脓皮病（PG）是一种罕见的非传染性中性粒细胞皮肤病，其特征为反复发作、疼痛的溃疡，通常影响下肢，但也可涉及身体的其他部位。超过一半的 PG 患者同时患有系统性自身免疫性疾病，PG 与系统性硬皮病（SSc）的关联极为罕见。PG 的治疗主要包括局部治疗、类固醇和免疫抑制剂，越来越重视生物制剂。其中，肿瘤坏死因子-α（TNF-α）拮抗剂被认为是有效的。本报告中的患者为一名老年女性，患有系统性硬皮病多年，最初表现为指尖坏疽性溃疡。在常规治疗无效后，加用阿达木单抗治疗 5 周，疾病得到抑制，溃疡缩小，6 个月后皮肤病变重新上皮化。
